Companies › Rapamycin Holdings
1 active drug program in 2 registered trials: 1 Phase 3, 1 Phase 2; Oncology; next expected readout Jul 2030.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Sirolimus FK506-binding protein 1A inhibitor | FKBP1A | Phase 3 | Familial Adenomatous Polyposis (FAP); Familial Adenomatous Polyposis | Jul 2030 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT04230499 | Sirolimus | Phase 2 | Familial Adenomatous Polyposis | Oncology | Dec 2024 |
| NCT06950385 | Sirolimus | Phase 3 | Familial Adenomatous Polyposis (FAP) | Oncology | Jul 2030 |
Eisai CSPC ZhongQi Pharmaceutical Technology Restorbio Novartis AgelessRx Novaliq Palvella Therapeutics Jiangsu Simcere Pharmaceutical Aadi Bioscience Eyestem Research
Aadi Bioscience Mercator MedSystems Verity Pharmaceuticals SecuraBio Fidia Farmaceutici
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.